Coeliac disease and gluten sensitivity

Journal of Internal Medicine

Volumn 269, Issue 6, 2011, Pages 582-590

  Troncone, R ^a   Jabri, B ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Anti tissue transglutaminase antibodies; Coeliac disease; Gluten sensitivity; Potential coeliac disease; Type 1 diabetes

Indexed keywords

GLIADIN; GLIADIN ANTIBODY; HLA DQ2 ANTIGEN; HLA DQ8 ANTIGEN; IMMUNOGLOBULIN M ANTIBODY; IRON; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE ANTIBODY;

ADAPTIVE IMMUNITY; ANTIBODY PRODUCTION; ANTIBODY TITER; ATAXIA; AUTOIMMUNITY; B LYMPHOCYTE ACTIVATION; CELIAC DISEASE; CONFERENCE PAPER; DERMATITIS HERPETIFORMIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE MARKER; ENTEROPATHY; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; GLUTEN ATAXIA; GLUTEN SENSITIVITY; HAPLOTYPE; HISTOPATHOLOGY; HLA TYPING; HUMAN; IMMUNOPATHOGENESIS; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; INTESTINE VILLUS ATROPHY; IRON DEFICIENCY ANEMIA; IRRITABLE COLON; LYMPHOCYTIC INFILTRATION; NONHUMAN; PRIORITY JOURNAL; SMALL INTESTINE MUCOSA; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE;

AUTOANTIBODIES; BIOLOGICAL MARKERS; CELIAC DISEASE; DIABETES MELLITUS, TYPE 1; DIAGNOSIS, DIFFERENTIAL; FOOD HYPERSENSITIVITY; GLUTENS; HUMANS; TRANSGLUTAMINASES;

EID: 79956265645     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2011.02385.x     Document Type: Conference Paper

References (48)

1. Jabri B, Sollid LM. Tissue-mediated control of immunopathology in coeliac disease. Nat Rev Immunol 2009; 9: 858-70.
2. Di Sabatino A, Corazza GR. Coeliac disease. Lancet 2009; 373: 1480-93.
3. Battais F, Richard C, Jacquenet S, Denery-Papini S, Moneret-Vautrin DA. Wheat grain allergies: an update on wheat allergens. Eur Ann Allergy Clin Immunol 2008; 40: 67-76.
4. Verdu EF, Armstrong D, Murray JA. Between celiac disease and irritable bowel syndrome: the "no man's land" of gluten sensitivity. Am J Gastroenterol 2009; 104: 1587-94.
5. Ferguson A, Arranz E, O'Mahony S. Clinical and pathological spectrum of coeliac disease: active, silent, latent, potential. Gut 1993; 34: 150-1.
6. Lundin KE, Nilsen EM, Scott HG et al. Oats induced villous atrophy in coeliac disease. Gut 2003; 52: 1649-52.
7. Silano M, Agostoni C, Guandalini S. Effect of the timing of gluten introduction on the development of celiac disease. World J Gastroenterol 2010; 16: 1939-42.
8. Troncone R, Auricchio S. Rotavirus and celiac disease: clues to the pathogenesis and perspectives on prevention. J Pediatr Gastroenterol Nutr 2007; 44: 527-8.
9. Nisticò L, Fagnani C, Coto I et al. Concordance, disease progression, and heritability of coeliac disease in Italian twins. Gut 2006; 55: 803-8.
10. Karell K, Louka AS, Moodie SJ et al. HLA types in celiac disease patients not carrying the DQA1*05-DQB1*02 (DQ2) heterodimer: results from the European Genetics Cluster on Celiac Disease. Hum Immunol 2003; 64: 469-77.
11. Vader W, Kooy Y, Van Veelen P et al. The gluten response in children with celiac disease is directed toward multiple gliadin and glutenin peptides. Gastroenterology 2002; 122: 1729-37.
12. Arentz-Hansen H, McAdam SN, Molberg Ø et al. Celiac lesion T cells recognize epitopes that cluster in regions of gliadins rich in proline residues. Gastroenterology 2002; 123: 803-9.
13. Vader LW, de Ru A, van der Wal Y et al. Specificity of tissue transglutaminase explains cereal toxicity in celiac disease. J Exp Med 2002; 195: 643-9.
14. Dørum S, Qiao SW, Sollid LM et al. A quantitative analysis of transglutaminase 2-mediated deamidation of gluten peptides: implications for the T-cell response in celiac disease. J Proteome Res 2009; 8: 1748-55.
15. Nilsen EM, Jahnsen FL, Lundin KE et al. Gluten induces an intestinal cytokine response strongly dominated by interferon gamma in patients with celiac disease. Gastroenterology 1998; 115: 551-63.
16. Fina D, Sarra M, Caruso R et al. Interleukin 21 contributes to the mucosal T helper cell type 1 response in coeliac disease. Gut 2008; 57: 887-92.
17. Monteleone G, Pender SL, Alstead E et al. Role of interferon alpha in promoting T helper cell type 1 responses in the small intestine in coeliac disease. Gut 2001; 48: 425-9.
18. Maiuri L, Ciacci C, Auricchio S et al. Interleukin 15 mediates epithelial changes in celiac disease. Gastroenterology 2000; 119: 996-1006.
19. Salvati VM, MacDonald TT, Bajaj-Elliott M et al. Interleukin 18 and associated markers of T helper cell type 1 activity in coeliac disease. Gut 2002; 50: 186-90.
20. Ferguson A, Murray D. Quantitation of intraepithelial lymphocytes in human jejunum. Gut 1971; 12: 988-94.
21. Jabri B, de Serre NP, Cellier C et al. Selective expansion of intraepithelial lymphocytes expressing the HLA-E-specific natural killer receptor CD94 in celiac disease. Gastroenterology 2000; 118: 867-79.
22. Roberts AI, Lee L, Schwartz E et al. NKG2D receptors induced by IL-15 costimulate CD28-negative effector CTL in the tissue microenvironment. J Immunol 2001; 167: 5527-30.
23. Meresse B, Chen Z, Ciszewski C et al. Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity 2004; 21: 357-66.
24. Hüe S, Mention JJ, Monteiro RC et al. A direct role for NKG2D/MICA interaction in villous atrophy during celiac disease. Immunity 2004; 21: 367-77.
25. Dieterich W, Ehnis T, Bauer M et al. Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med 1997; 3: 797-801.
26. Tosco A, Salvati VM, Auricchio R et al. Most children with potential celiac disease are healthy but one third of them develop villous atrophy at 3-years follow-up. Clin Gastroenterol Hepatol 2011; 9: 320-5.
27. Bourgey M, Calcagno G, Tinto N et al. HLA related genetic risk for celiac disease. Gut 2007; 56: 1054-9.
28. Vader W, Stepniak D, Kooy Y et al. The HLA-DQ2 gene dose effect in celiac disease is directly related to the magnitude and breadth of gluten-specific T cell responses. Proc Natl Acad Sci U S A 2003; 100: 12390-5.
29. Tiittanen M, Westerholm-Ormio M, Verkasalo M et al. Infiltration of forkhead box P3-expressing cells in small intestinal mucosa in celiac disease but not in type 1 diabetes. Clin Exp Immunol 2008; 152: 498-507.
30. Hull CM, Liddle M, Hansen N et al. Elevation of IgA anti-epidermal transglutaminase antibodies in dermatitis herpetiformis. Br J Dermatol 2008; 159: 120-4.
31. Marietta EV, Camilleri MJ, Castro LA et al. Transglutaminase autoantibodies in dermatitis herpetiformis and celiac sprue. J Invest Dermatol 2008; 128: 332-5.
32. Dahlbom I, Korponay-Szabó IR, Kovács JB et al. Prediction of clinical and mucosal severity of coeliac disease and dermatitis herpetiformis by quantification of IgA/IgG serum antibodies to tissue transglutaminase. J Pediatr Gastroenterol Nutr 2010; 50: 140-6.
33. Hadjivassiliou M, Sanders DS, Grünewald RA et al. Gluten sensitivity: from gut to brain. Lancet Neurol 2010; 9: 318-30.
34. Hadjivassiliou M, Mäki M, Sanders DS et al. Autoantibody targeting of brain and intestinal transglutaminase in gluten ataxia. Neurology 2006; 66: 373-7.
35. Stamnaes J, Dorum S, Fleckenstein B et al. Gluten T cell epitope targeting by TG3 and TG6; implications for dermatitis herpetiformis and gluten ataxia. Amino Acids 2010; 39: 1183-91.
36. Spiegel BM, DeRosa VP, Gralnek IM et al. Testing for celiac sprue in irritable bowel syndrome with predominant diarrhea: a cost-effectiveness analysis. Gastroenterology 2004; 126: 1721-32.
37. Rodríguez LA, Ruigómez A. Increased risk of irritable bowel syndrome after bacterial gastroenteritis: cohort study. BMJ 1999; 318: 565-6.
38. Arranz E, Ferguson A. Intestinal antibody pattern of celiac disease: occurrence in patients with normal jejunal biopsy histology. Gastroenterology 1993; 104: 1263-72.
39. Wahnschaffe U, Schulzke JD, Zeitz M et al. Predictors of clinical response to gluten-free diet in patients diagnosed with diarrhea-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 2007; 5: 844-50.
40. Troncone R, Greco L, Mayer M et al. In siblings of celiac children, rectal gluten challenge reveals gluten sensitization not restricted to celiac HLA. Gastroenterology 1996; 111: 318-24.
41. Michaëlsson G, Gerdén B, Hagforsen E et al. Psoriasis patients with antibodies to gliadin can be improved by a gluten-free diet. Br J Dermatol 2000; 142: 44-51.
42. O'Farrelly C. Wheat protein sensitive disease may be independent of intestinal structural changes. In: Feighery C, O'Farrelly C, eds Gastrointestinal Immunology and Gluten-Sensitive Disease. Dublin: Oak Tree Press, 1992; 169-80.
43. Mallone R, van Endert P. T cells in the pathogenesis of type 1 diabetes. Curr Diab Rep 2008; 8: 101-6.
44. Vaarala O, Atkinson MA, Neu J. The "perfect storm" for type 1 diabetes: the complex interplay between intestinal microbiota, gut permeability, and mucosal immunity. Diabetes 2008; 57: 2555-62.
45. Maki M, Hallstrom O, Huupponen T et al. Increased prevalence of coeliac disease in diabetes. Arch Dis Child 1984; 59: 739-42.
46. Troncone R, Franzese A, Mazzarella G et al. Gluten sensitivity in a subset of children with insulin dependent diabetes mellitus. Am J Gastroenterol 2003; 98: 590-5.
47. Auricchio R, Paparo F, Maglio M et al. In vitro-deranged intestinal immune response to gliadin in type 1 diabetes. Diabetes 2004; 53: 1680-3.
48. Ventura A, Magazzù G, Greco L. Duration of exposure to gluten and risk for autoimmune disorders in patients with coeliac disease. SIGEP Study Group for Autoimmune Disorders in Coeliac Disease. Gastroenterology 1999; 117: 297-303.